Developer docs
API playgroundTry for free, no card

Search company profiles

Superluminal Medicines

Full company profile

uuid00005ty

Namestring
Superluminal Medicines
Legal namestring
Superluminal Medicines, Inc.
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Superluminal Medicines is a Boston-based, venture-backed drug discovery company founded in 2023 that integrates AI/ML, protein dynamics simulation, and cryoEM-based structural biology to discover small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company operates its Hyperloop™ Platform, which combines proprietary Target GPS™ for predicting GPCR protein conformations (including for proteins lacking experimental structures), ADME DRIVE™ for AI/ML-based ADMET prediction, giga-scale virtual screening, generative AI for de novo molecule design, and access to multiple cryoEM microscopes for routine high-resolution structure generation. Its pipeline includes a selective, biased MC4R agonist advancing to IND-enabling studies for obesity (retained in-house) plus multiple GPCR programs (2-5) targeting cardiometabolic diseases.

The company monetizes exclusively through B2B strategic partnerships with large pharmaceutical companies, using an enterprise field-sales model and a deal structure that combines upfront payments, equity investments, development and commercial milestones, and tiered royalties on net sales. Its flagship commercial relationship is the August 2025 collaboration with Eli Lilly worth up to $1.3 billion for undisclosed GPCR targets in cardiometabolic diseases and obesity, with a secondary Axcelead DDP collaboration announced in June 2025. The company also engages in collaborative research funded by partners targeting specific GPCRs. Total equity raised is approximately $153 million ($33M seed in Aug 2023 led by RA Capital Management, $120M Series A in Sep 2024 also led by RA Capital Management), with additional strategic backers including Insight Partners, NVIDIA, Gaingels, Catalio Capital Management, and Eli Lilly.

Superluminal's primary customer segment is large pharmaceutical and biotech companies seeking differentiated AI-driven drug discovery for challenging GPCR targets. The company is headquartered at Lilly Gateway Labs in Boston, MA, is incorporated as Superluminal Medicines, Inc. in Massachusetts, and operates with a leadership team including CEO Cony D'Cruz, CSO Ajay Yekkirala, CFO Murco Ringnalda, and SVP Business Development Ryan Bloom, supported by a Scientific Advisory Board chaired by Morris J. Birnbaum. Infrastructure dependencies include Google Cloud (Vertex AI, BigQuery, Gemini), NVIDIA compute, and Rhino Federated Computing for participation in Eli Lilly's TuneLab.

Short descriptiontext

Superluminal Medicines is a Boston-based drug discovery company using its Hyperloop™ AI platform—combining protein dynamics, generative chemistry, and cryoEM structural biology—to discover small-molecule GPCR therapeutics. It serves large pharmaceutical firms through co-development and licensing partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, small molecule therapeutics, GPCR targeted medicines, computational drug design, structure-based discovery
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI-powered drug discovery services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Licensing Deals
TypeLicensing Royalties
Description

Superluminal generates revenue through strategic partnerships with pharmaceutical companies involving upfront payments, equity investments, development and commercial milestone payments, and tiered royalties on net sales of approved drugs. The company retains ownership of certain pipeline assets while granting exclusive development and commercialization rights to partners for specified targets.

manufacturing.economictimes.indiatimes.com
2Collaborative Research Funding
TypeProfessional Services
Description

Revenue from collaborative research agreements where partners fund specific drug discovery programs targeting agreed-upon GPCRs and therapeutic areas.

superluminalrx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Superluminal Medicines operates a generative biology and chemistry drug discovery business centered on its Hyperloop™ Platform, which combines AI/ML, protein dynamics, giga-scale virtual screening, generative molecule design, and cryoEM-based structural biology to identify and develop small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company delivers these capabilities through strategic co-development and licensing partnerships with large pharmaceutical companies, retaining rights to selected pipeline assets such as its biased MC4R agonist for rare genetic obesity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Routinely generates dozens of high-resolution proprietary protein structures per month
+2 more records
Product overview1 text field

Superluminal Medicines operates as a drug discovery company built around its Hyperloop™ Platform—an integrated computational and experimental suite that unifies protein dynamics prediction (Target GPS™), generative AI molecule design, giga-scale virtual screening, and ADMET profiling (ADME DRIVE™). The platform supports a pipeline of small-molecule GPCR-targeted drug candidates, including a biased MC4R agonist advancing toward IND filing and multiple programs in lead optimization targeting cardiometabolic diseases.

Product and service5 records
1Hyperloop™ Platform
CategoryAI drug discovery platform
Description

Integrated computational and experimental drug discovery platform combining AI/ML, protein dynamics simulation, giga-scale virtual screening, generative molecule design, ADMET prediction, and cryoEM structural biology to discover small-molecule therapeutics against GPCRs. Used in-house and with pharma partners such as Eli Lilly.

2Target GPS™
CategoryAI protein conformation prediction
Description

Proprietary AI/ML method that predicts protein conformations and creates dynamic ensemble models of GPCRs in days rather than months, including for proteins that lack experimental structures. Supports structure-based drug design within the Hyperloop™ platform.

3ADME DRIVE™
CategoryADMET prediction software
Description

AI/ML-based ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction tools that enable earlier and more accurate candidate selection by combining public, private, and proprietary data sources.

4MC4R Program (biased MC4R agonist for obesity)
CategoryDrug pipeline candidate
Description

Wholly owned small-molecule program: a selective, biased melanocortin 4 receptor (MC4R) agonist designed to activate only relevant MC4R signaling pathways, offering a broad therapeutic window while avoiding side effects. Advancing to IND-enabling studies for obesity, including rare genetic obesity forms.

5GPCR Pipeline Programs (cardiometabolic small molecules)
CategoryDrug pipeline candidates
Description

Portfolio of small-molecule GPCR-targeted discovery programs spanning multi-functional ligands, PAMs/NAMs, and antagonists aimed at cardiometabolic diseases, blending scientific innovation with patient-centric precision medicine.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-09-09
Description

Provides federated computing technology enabling Superluminal to participate in Eli Lilly's TuneLab platform, allowing collaborative AI model training without sharing raw proprietary data.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-18
Description

Up to $1.3 billion collaboration to discover and develop small-molecule drugs targeting undisclosed GPCRs for cardiometabolic diseases and obesity. Deal includes upfront payments, equity investment, development and commercial milestones, and tiered royalties on net sales. Superluminal retains a lead MC4R program for rare genetic obesity while Lilly gains exclusive rights to other candidates.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Collaboration on drug discovery targeting specific molecular mechanisms, continuing a productive relationship between the two companies for joint drug discovery efforts.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-09
Description

Superluminal leverages Google Cloud's infrastructure including Vertex AI Model Garden, BigQuery, and Gemini model capabilities for molecule generation, drug repurposing, and synthetic data creation as part of their AI-driven drug discovery pipeline.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-driven protein engineering platform using generative models to design novel biologics; adjacent in AI drug discovery approach though focused on protein design rather than GPCR small molecules.

TypeBroad incumbent
Description

Eli Lilly's externalized R&D arm that partners with AI-driven discovery companies including Superluminal; represents the customer/incumbent side of the AI drug discovery partnership model.

TypeDirect peer
Description

Computational drug discovery platform combining physics-based simulation with ML for small molecule discovery; partners with pharma on structure-based and AI-driven programs targeting similar audiences as Superluminal.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with ML to identify novel therapeutics; targets similar pharma partnership model with platform-based small molecule and biologic programs.

TypeDirect peer
Description

AI-driven precision medicine company using generative AI to design novel small molecules; competes directly in pharma partnership and pipeline development model focused on challenging targets.

TypeDirect peer
Description

Machine learning-driven drug discovery company combining high-throughput biology with predictive models to accelerate small molecule and biologic pipeline development for pharma partners.

TypeDirect peer
Description

AI-driven small molecule discovery company using structure-based virtual screening and ML to identify leads; partners with pharma and pursues proprietary pipeline across multiple therapeutic areas.

8Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company applying deep learning to predict protein structures and design small molecules; targets similar pharma partnership opportunities with deep-pocketed backers.

TypeEmerging player
Description

Generative AI biology platform for novel protein therapeutics; overlaps in AI-driven drug discovery methodology though focused on biologics rather than small molecules.

10Iambic Therapeutics
TypeDirect peer
Description

AI-driven drug discovery company combining physics-based and ML approaches to design small molecule therapeutics; pursues similar pharma partnership model and proprietary pipeline development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Superluminal Medicines

AI-powered drug discovery servicessuperluminalrx.com

Superluminal Medicines is a Boston-based drug discovery company using its Hyperloop™ AI platform—combining protein dynamics, generative chemistry, and cryoEM structural biology—to discover small-molecule GPCR therapeutics. It serves large pharmaceutical firms through co-development and licensing partnerships.

What Superluminal Medicines does

Superluminal Medicines is a Boston-based, venture-backed drug discovery company founded in 2023 that integrates AI/ML, protein dynamics simulation, and cryoEM-based structural biology to discover small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company operates its Hyperloop™ Platform, which combines proprietary Target GPS™ for predicting GPCR protein conformations (including for proteins lacking experimental structures), ADME DRIVE™ for AI/ML-based ADMET prediction, giga-scale virtual screening, generative AI for de novo molecule design, and access to multiple cryoEM microscopes for routine high-resolution structure generation. Its pipeline includes a selective, biased MC4R agonist advancing to IND-enabling studies for obesity (retained in-house) plus multiple GPCR programs (2-5) targeting cardiometabolic diseases.

The company monetizes exclusively through B2B strategic partnerships with large pharmaceutical companies, using an enterprise field-sales model and a deal structure that combines upfront payments, equity investments, development and commercial milestones, and tiered royalties on net sales. Its flagship commercial relationship is the August 2025 collaboration with Eli Lilly worth up to $1.3 billion for undisclosed GPCR targets in cardiometabolic diseases and obesity, with a secondary Axcelead DDP collaboration announced in June 2025. The company also engages in collaborative research funded by partners targeting specific GPCRs. Total equity raised is approximately $153 million ($33M seed in Aug 2023 led by RA Capital Management, $120M Series A in Sep 2024 also led by RA Capital Management), with additional strategic backers including Insight Partners, NVIDIA, Gaingels, Catalio Capital Management, and Eli Lilly.

Superluminal's primary customer segment is large pharmaceutical and biotech companies seeking differentiated AI-driven drug discovery for challenging GPCR targets. The company is headquartered at Lilly Gateway Labs in Boston, MA, is incorporated as Superluminal Medicines, Inc. in Massachusetts, and operates with a leadership team including CEO Cony D'Cruz, CSO Ajay Yekkirala, CFO Murco Ringnalda, and SVP Business Development Ryan Bloom, supported by a Scientific Advisory Board chaired by Morris J. Birnbaum. Infrastructure dependencies include Google Cloud (Vertex AI, BigQuery, Gemini), NVIDIA compute, and Rhino Federated Computing for participation in Eli Lilly's TuneLab.

Superluminal Medicines firmographics

Firmographics
Name
Superluminal Medicines
Legal name
Superluminal Medicines, Inc.
Website
https://superluminalrx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Superluminal Medicines is a Boston-based drug discovery company using its Hyperloop™ AI platform—combining protein dynamics, generative chemistry, and cryoEM structural biology—to discover small-molecule GPCR therapeutics. It serves large pharmaceutical firms through co-development and licensing partnerships.
Ownership category
akta.pro rank

Superluminal Medicines industry classification

Industry
Product category
AI-powered drug discovery services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Small molecule therapeutics
  • GPCR targeted medicines
  • Computational drug design
  • Structure-based discovery

Where Superluminal Medicines is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Superluminal Medicines business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Partnership and Licensing Deals: Superluminal generates revenue through strategic partnerships with pharmaceutical companies involving upfront payments, equity investments, development and commercial milestone payments, and tiered royalties on net sales of approved drugs. The company retains ownership of certain pipeline assets while granting exclusive development and commercialization rights to partners for specified targets.
  2. Collaborative Research Funding: Revenue from collaborative research agreements where partners fund specific drug discovery programs targeting agreed-upon GPCRs and therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Superluminal Medicines product offering

Product offering

Core offering

Superluminal Medicines operates a generative biology and chemistry drug discovery business centered on its Hyperloop™ Platform, which combines AI/ML, protein dynamics, giga-scale virtual screening, generative molecule design, and cryoEM-based structural biology to identify and develop small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company delivers these capabilities through strategic co-development and licensing partnerships with large pharmaceutical companies, retaining rights to selected pipeline assets such as its biased MC4R agonist for rare genetic obesity.

Product overview

Superluminal Medicines operates as a drug discovery company built around its Hyperloop™ Platform—an integrated computational and experimental suite that unifies protein dynamics prediction (Target GPS™), generative AI molecule design, giga-scale virtual screening, and ADMET profiling (ADME DRIVE™). The platform supports a pipeline of small-molecule GPCR-targeted drug candidates, including a biased MC4R agonist advancing toward IND filing and multiple programs in lead optimization targeting cardiometabolic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hyperloop™ Platform Integrated computational and experimental drug discovery platform combining AI/ML, protein dynamics simulation, giga-scale virtual screening, generative molecule design, ADMET prediction, and cryoEM structural biology to discover small-molecule therapeutics against GPCRs. Used in-house and with pharma partners such as Eli Lilly.
  • Target GPS™ Proprietary AI/ML method that predicts protein conformations and creates dynamic ensemble models of GPCRs in days rather than months, including for proteins that lack experimental structures. Supports structure-based drug design within the Hyperloop™ platform.
  • ADME DRIVE™ AI/ML-based ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction tools that enable earlier and more accurate candidate selection by combining public, private, and proprietary data sources.
  • MC4R Program (biased MC4R agonist for obesity) Wholly owned small-molecule program: a selective, biased melanocortin 4 receptor (MC4R) agonist designed to activate only relevant MC4R signaling pathways, offering a broad therapeutic window while avoiding side effects. Advancing to IND-enabling studies for obesity, including rare genetic obesity forms.
  • GPCR Pipeline Programs (cardiometabolic small molecules) Portfolio of small-molecule GPCR-targeted discovery programs spanning multi-functional ligands, PAMs/NAMs, and antagonists aimed at cardiometabolic diseases, blending scientific innovation with patient-centric precision medicine.

Quantifiable outcome

  • Routinely generates dozens of high-resolution proprietary protein structures per month
  • +2 more outcomes

Companies that use Superluminal Medicines

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Superluminal Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Superluminal Medicines partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered supporting, flagship and core.

  • Rhino Federated ComputingsupportingTechnology or Integration · 9 September 2025Provides federated computing technology enabling Superluminal to participate in Eli Lilly's TuneLab platform, allowing collaborative AI model training without sharing raw proprietary data.
  • Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 18 August 2025Up to $1.3 billion collaboration to discover and develop small-molecule drugs targeting undisclosed GPCRs for cardiometabolic diseases and obesity. Deal includes upfront payments, equity investment, development and commercial milestones, and tiered royalties on net sales. Superluminal retains a lead MC4R program for rare genetic obesity while Lilly gains exclusive rights to other candidates.
  • Axcelead DDPcoreStrategic or Co-development Partner · 1 June 2025Collaboration on drug discovery targeting specific molecular mechanisms, continuing a productive relationship between the two companies for joint drug discovery efforts.
  • Google CloudcoreTechnology or Integration · 9 January 2025Superluminal leverages Google Cloud's infrastructure including Vertex AI Model Garden, BigQuery, and Gemini model capabilities for molecule generation, drug repurposing, and synthetic data creation as part of their AI-driven drug discovery pipeline.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Superluminal Medicines competitors and assessment

Company assessment

Emerging players

  • Cradle Bio: AI-driven protein engineering platform using generative models to design novel biologics; adjacent in AI drug discovery approach though focused on protein design rather than GPCR small molecules.
  • Generate Biomedicines: Generative AI biology platform for novel protein therapeutics; overlaps in AI-driven drug discovery methodology though focused on biologics rather than small molecules.

Broad incumbents

  • Eli Lilly Catalyze360: Eli Lilly's externalized R&D arm that partners with AI-driven discovery companies including Superluminal; represents the customer/incumbent side of the AI drug discovery partnership model.

Direct peers

  • Schrödinger: Computational drug discovery platform combining physics-based simulation with ML for small molecule discovery; partners with pharma on structure-based and AI-driven programs targeting similar audiences as Superluminal.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to identify novel therapeutics; targets similar pharma partnership model with platform-based small molecule and biologic programs.
  • Exscientia: AI-driven precision medicine company using generative AI to design novel small molecules; competes directly in pharma partnership and pipeline development model focused on challenging targets.
  • Insitro: Machine learning-driven drug discovery company combining high-throughput biology with predictive models to accelerate small molecule and biologic pipeline development for pharma partners.
  • Atomwise: AI-driven small molecule discovery company using structure-based virtual screening and ML to identify leads; partners with pharma and pursues proprietary pipeline across multiple therapeutic areas.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to predict protein structures and design small molecules; targets similar pharma partnership opportunities with deep-pocketed backers.
  • Iambic Therapeutics: AI-driven drug discovery company combining physics-based and ML approaches to design small molecule therapeutics; pursues similar pharma partnership model and proprietary pipeline development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Superluminal Medicines social profiles

Digital presence

Superluminal Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Superluminal Medicines leadership team

Management profile

Number of profiles

Profiles9 records

Superluminal Medicines funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Superluminal Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Superluminal Medicines

What does Superluminal Medicines do?

Superluminal Medicines operates a generative biology and chemistry drug discovery business centered on its Hyperloop™ Platform, which combines AI/ML, protein dynamics, giga-scale virtual screening, generative molecule design, and cryoEM-based structural biology to identify and develop small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company delivers these capabilities through strategic co-development and licensing partnerships with large pharmaceutical companies, retaining rights to selected pipeline assets such as its biased MC4R agonist for rare genetic obesity.

Is Superluminal Medicines a public or private company?

Superluminal Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was Superluminal Medicines founded?

Superluminal Medicines was founded in 2023. It employs 51 to 100 people.

Where is Superluminal Medicines based?

Superluminal Medicines is headquartered in Boston, United States, in the North America region.

How does Superluminal Medicines make money?

Two revenue lines are on record. Partnership and Licensing Deals are the primary driver. The others are collaborative Research Funding.

Who are Superluminal Medicines's main competitors?

Emerging players on record are Cradle Bio and Generate Biomedicines. Eli Lilly Catalyze360 is listed as a broad incumbent. Direct peers are Schrödinger, Recursion Pharmaceuticals, Exscientia, Insitro, Atomwise, Isomorphic Labs and Iambic Therapeutics.

Does Superluminal Medicines have an API?

No public API is recorded for Superluminal Medicines.

What industry is Superluminal Medicines in?

Superluminal Medicines's product category is AI-powered drug discovery services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WowtaleGPCR 신약개발 AI 슈퍼루미널, 6천만 달러 시리즈B 유치Superluminal Medicines raised $60 million in a Series B led by BVF Partners, exceeding its target. The Boston biotech uses AI and cryo-EM to target GPCRs, with a pipeline targeting MC4R for rare genetic obesity, aiming for Phase 1 this year. It also partners with Eli Lilly on cardiovascular and metabolic GPCR targets.Pulse 2.0Superluminal Medicines Raises $60 Million Series B Led By BVF PartnersSuperluminal Medicines raised $60 million in a Series B led by BVF Partners to advance its lead obesity program into clinical development. The company expects a Phase 1 trial to begin by the end of 2026 for its selective MC4R agonist targeting rare genetic forms of obesity.Pharmaceutical TechnologySuperluminal Medicines secures $60m to advance rare obesity therapySuperluminal Medicines raised $60M in a Series B led by BVF Partners to advance its MC4R agonist for rare genetic obesity. The company plans to move the lead candidate into a Phase I trial by year-end and expand its pipeline for cardiometabolic diseases.The Pharma LetterSuperluminal raises $60 million to take obesity drug into clinicSuperluminal Medicines closed a $60 million Series B led by BVF Partners to advance its lead obesity drug into human testing. The Boston biotech's Phase I trial is due to start by the end of 2026, marking its first clinical program.BioPharma DiveAn AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines raised $60 million to advance its MC4R-activating drug for rare obesity into human testing by year-end. The company has raised $213 million total and partners with Eli Lilly. It may test against Prader-Willi syndrome, facing competition from Vykat XR and Imcivree.AijournSuperluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the ClinicSuperluminal Medicines closed an oversubscribed $60 million Series B financing led by BVF Partners. Proceeds will support a Phase 1 clinical trial for its MC4R agonist in rare genetic obesity by end of 2026. The company plans to expand its GPCR-focused discovery platform and pipeline.Unite.AISuperluminal Medicines Raises $60M Series B to Advance Obesity DrugSuperluminal Medicines closed a $60 million Series B led by BVF Partners, advancing its MC4R agonist for rare genetic obesity. Proceeds will support a Phase 1 trial by end of 2026 and expansion of its GPCR discovery platform. The company also has a collaboration with Eli Lilly for undisclosed GPCR targets.Endpoints NewsSuperluminal secures $60M for Phase 1 of genetic obesity drugSuperluminal, a Boston biotech, raised $60 million to test its genetic obesity drug approach. The company follows Rhythm Pharmaceuticals and others in the MC4R obesity field.MorningstarSuperluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the ClinicSuperluminal Medicines closed an oversubscribed $60 million Series B financing led by BVF Partners. Proceeds will support a Phase 1 clinical trial for its MC4R agonist in rare genetic obesity, expected to begin by end of 2026, and expand its GPCR-focused pipeline.MarketScreenerSuperluminal Medicines, Inc. announced that it has received $60 million in funding from a group of investorsSuperluminal Medicines, Inc. closed a $60 million funding round on September 3, 2026, with participation from 16 investors. The round was led by new investor BVF Partners L.P., with existing investors including Eli Lilly and Company.